论文部分内容阅读
目的:观察疏血通联合脑蛋白水解物治疗急性脑梗死的临床疗效。方法:将108例急性脑梗死患者随机分为治疗组和对照组各54例。两组患者均按照急性脑梗死常规治疗方案进行干预,对照组在常规治疗方案的基础上加用脑蛋白水解物静脉滴注,治疗组在对照组治疗方案的基础上加用疏血通注射液静脉滴注。治疗2周后,对比两组患者的临床疗效及神经功能缺损评分(NIHSS)的变化情况;并观察治疗过程中不良反应的发生情况。结果:愈显率治疗组为81.48%,对照组为61.11%,组间比较,差异有统计学意义(P<0.05);两组患者治疗第7天和第14天的NIHSS评分治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05)。结论:疏血通联合脑蛋白水解物可改善急性脑梗死患者的临床疗效,且具有良好的安全性,可资临床借鉴。
Objective: To observe the clinical effect of Shuxuetong combined with brain protein hydrolyzate in the treatment of acute cerebral infarction. Methods: 108 patients with acute cerebral infarction were randomly divided into treatment group and control group of 54 cases. Two groups of patients were in accordance with the conventional treatment of acute cerebral infarction intervention, the control group on the basis of conventional treatment plus brain protein hydrolyzate intravenous infusion, the treatment group in the control group based on the treatment program with Shuxuetong injection Intravenous infusion. After 2 weeks of treatment, the clinical efficacy and changes of neurological deficit score (NIHSS) were compared between the two groups. The incidence of adverse reactions during the course of treatment was also observed. Results: The cure rate was 81.48% in the treatment group and 61.11% in the control group. The differences between the two groups were statistically significant (P <0.05). The NIHSS scores on the 7th and 14th days Comparing and after treatment, the differences were statistically significant (P <0.05). Conclusion: Shuxuetong combined with brain protein hydrolyzate can improve the clinical efficacy of patients with acute cerebral infarction, and has good safety, available for clinical reference.